喘息・COPD療法の世界市場2020-2030

【英語タイトル】Asthma & COPD Therapies Market Report 2020-2030

visiongainが出版した調査資料(VGA20DE020)・商品コード:VGA20DE020
・発行会社(調査会社):visiongain
・発行日:2020年9月
・ページ数:318
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後24時間以内)
・調査対象地域:グローバル
・産業分野:医療
◆販売価格オプション(消費税別)
Sigle User(1名様閲覧用)USD5,850 ⇒換算¥608,400見積依頼/購入/質問フォーム
Global Site License(法人閲覧用)USD9,099 ⇒換算¥946,296見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Discover sales predictions for the world market and submarkets
By Treatment:
• Bronchodilator Monotherapy
• Anticholinergics: Spiriva, Atrovent, Eklira, Others
• SABA: Ventolin, ProAir, Proventil, Xoponex, Others
• LABA: Foradil, Arcapta/Onbrez, Brovana, Serevent, Others
• Anti-Inflammatory Drugs
• Corticosteroids: Pulmicort, Flixotide, QVAR, Asmanex, Others
• Anti-Leukotrienes: Singulair, Others
• Monoclonal Antibodies: Xolair, Cinqair, Nucala, Benralizumab, Lebrikizumab, Dupilumab
• Others
• Combination Drugs
• Advair
• Symbicort
• Combivent
• Dulera
• Relvar/Breo
• Others
By Route of Administration:
• Oral
• Inhaled
• Others
By Point of Sale/Distribution Channel:
• Retail pharmacies
• Hospital pharmacies
• Others
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 4 regional and 10 leading national markets:

By Region:
• North America
• U.S.
• Canada
• Europe
• Germany
• France
• UK
• Italy
• Spain
• Rest of Europe
• Asia Pacific
• China
• Japan
• India
• Rest of APAC
• Rest of the World
The report also includes profiles and for some of the leading companies in the COPD and asthma therapeutics Market, with a focus on this segment of these companies’ operations.

There will be growth in both established and in developing countries. Our analyses show that the both developed and developing markets, U.S., Germany, UK and Japan, China in particular, will continue to achieve high revenue growth to 2030.

Leading companies and the potential for market growth

Overall world revenue for COPD and Asthma Therapeutics Market will surpass US$ xx million in 2020, our work calculates. We predict strong revenue growth through to 2030.

Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How the COPD and Asthma Therapeutics Market report helps you

In summary, our 310+ page report provides you with the following knowledge:
• Revenue forecasts to 2030 for COPD and Asthma Therapeutics Market, with forecasts for Treatment, Route of Administration, and Distribution Channel, each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues
• Revenue forecasts to 2030 for 4 regional and 10 key national markets – See forecasts for the COPD and Asthma Therapeutics market in North America, Europe, Asia-Pacific and Rest of the World. Also forecasted is the market in the US, Canada, Germany, France, UK, Italy, Spain, China, India, and Japan.
• Prospects for established firms and those seeking to enter the market– including company profiles for 12 of the major companies involved in the COPD and Asthma Therapeutics Market. Some of the company’s profiles in this report include AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Teva, Merck, F. Hoffmann-La Roche AG.
Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

The publisher is using a password system to access all reports. Single user (non-printable) and departmental licenses expires after 12 month period. In the case of departmental site license purchases, the publisher requires all email addresses for the licensed users prior to fulfillment.

【レポートの目次】

1. Global COPD and Asthma Therapies Market 2020-2030
1.1 Introduction
1.2 Why You Should Read This Report
1.3 What This Report Delivers
1.4 Key Questions Answered by This Analytical Report Include:
1.5 Who is This Report For?
1.6 Methodology
1.7 Frequently Asked Questions (FAQs)
1.8 Associated Visiongain Reports
1.9 About Visiongain
2 Executive Summary
3 Introduction to the COPD and Asthma Therapies Market
3.1 Introduction to the COPD and Asthma Therapies
3.2 The Pharmaceutical Industry: A Very Brief Overview
3.3 What is Asthma?
3.3.1 Trends in Asthma Prevalence
3.3.2 Pathophysiology of Asthma
3.3.3 Symptoms of Asthma
3.3.4 Causes and Triggers for Asthma
3.3.5 Treatment of Asthma
3.3.6 Drug Delivery Methods in Asthma
3.4 What is Chronic Obstructive Pulmonary Disease (COPD)?
3.4.1 Trends in COPD Prevalence
3.4.2 Pathophysiology of COPD
3.4.3 Signs and Symptoms of COPD
3.4.4 Treatment of COPD
3.4.5 Drug Treatments for COPD
3.4.6 Guidelines for COPD Treatment
3.5 Major Drug Classes in the Treatment of Asthma and COPD
3.5.1 Bronchodilators
3.5.1.1 Beta2-Agonists
3.5.1.2 Anticholinergics
3.5.2 Anti-Inflammatory Drugs
3.5.2.1 Corticosteroids
3.5.2.2 Leukotriene Receptor Antagonists
3.5.2.3 Monoclonal Antibodies in the Treatment of Respiratory Disease
3.5.3 Combination Drugs
4 Industry Insights
4.1 Market Drivers
4.1.1 Increasing prevalence of respiratory diseases on account of increasing pollution
4.1.2 Reducing social stigma asthma and COPD
4.1.3 Strong pipeline for asthma drugs
4.2 Market Restraints/Challenges
4.3 Market Opportunities
4.3.1 Telehealth
4.4 Porter’s five forces
4.4.1 Bargaining Power of Buyers
4.4.2 Bargaining Power of Suppliers
4.4.3 Threat of Substitutes
4.4.4 Threat of New Entrants
4.4.5 Industry Rivalry
4.5 SWOT Analysis
4.5.1 Strength
4.5.1.1 Increasing Prevalence and Disease Burden
4.5.1.2 Advanced Inhaler Technologies
4.5.1.3 High Costs of Treatment
4.5.1.4 The Changing Perception of COPD
4.5.1.5 Developments in Diagnostics
4.5.2 Weakness
4.5.2.1 Low awareness levels in low income groups
4.5.2.2 Patent Cliff for Devices
4.5.2.3 Side-Effects of Drug Classes
4.5.2.4 Costing Pressures in both Developed and Emerging Markets
4.5.3 Opportunities
4.5.3.1 Strong R&D
4.5.3.2 Vast pipeline by numerous players
4.5.3.3 Emergence of telehealth
4.5.4 Threats
4.5.4.1 Patent Expiry
4.5.4.2 The WISDOM Trial Could Reduce Steroid Use in COPD
5 Global COPD and Asthma Therapies Market by Treatment
5.1 Medication Submarket Forecast 2020-2030
5.1.1 Anti-inflammatory drugs Submarket Forecast 2020-2030
5.1.1.1 V Shaped Recovery: Global COPD and Asthma Therapies Market for Anti-Inflammatory Segment forecast, 2020 to 2030
5.1.1.2 U Shaped Recovery: Global COPD and Asthma Therapies Market for Anti-Inflammatory Segment forecast, 2020 to 2030
5.1.1.3 W Shaped Recovery: Global COPD and Asthma Therapies Market for Anti-Inflammatory Segment forecast, 2020 to 2030
5.1.1.4 L Shaped Recovery: Global COPD and Asthma Therapies Market for Anti-Inflammatory Segment forecast, 2020 to 2030
5.1.1.5 Corticosteroids Submarket Forecast 2020-2030
5.1.1.5.1 Pulmicort Submarket Forecast 2020-2030
5.1.1.5.2 Flixotide Submarket Forecast 2020-2030
5.1.1.5.3 QVAR Submarket Forecast 2020-2030
5.1.1.5.4 Asmanex Submarket Forecast 2020-2030
5.1.1.5.5 Others Submarket Forecast 2020-2030
5.1.1.6 Anti-Leukotrienes Submarket Forecast 2020-2030
5.1.1.6.1 Singulair Submarket Forecast 2020-2030
5.1.1.6.2 Others Submarket Forecast 2020-2030
5.1.1.7 Monoclonal Antibodies Submarket Forecast 2020-2030
5.1.1.7.1 Xolair Submarket Forecast 2020-2030
5.1.1.7.2 Cinqair Submarket Forecast 2020-2030
5.1.1.7.3 Nucala Submarket Forecast 2020-2030
5.1.1.7.4 Benralizumab Submarket Forecast 2020-2030
5.1.1.7.5 Lebrikizumab Submarket Forecast 2020-2030
5.1.1.7.6 Dupilumab Submarket Forecast 2020-2030
5.1.2 Bronchodilator Monotherapy Submarket Forecast 2020-2030
5.1.2.1 V Shaped Recovery: Global COPD and Asthma Therapies Market for Bronchodilator Monotherapy Segment forecast, 2020 to 2030
5.1.2.2 U Shaped Recovery: Global COPD and Asthma Therapies Market for Bronchodilator Monotherapy Segment forecast, 2020 to 2030
5.1.2.3 W Shaped Recovery: Global COPD and Asthma Therapies Market for Bronchodilator Monotherapy Segment forecast, 2020 to 2030
5.1.2.4 L Shaped Recovery: Global COPD and Asthma Therapies Market for Bronchodilator Monotherapy Segment forecast, 2020 to 2030
5.1.2.5 Anticholinergics Submarket Forecast 2020-2030
5.1.2.5.1 Spiriva Submarket Forecast 2020-2030
5.1.2.5.2 Atrovent Submarket Forecast 2020-2030
5.1.2.5.3 Eklira Submarket Forecast 2020-2030
5.1.2.5.4 Others Submarket Forecast 2020-2030
5.1.2.6 SABA Submarket Forecast 2020-2030
5.1.2.6.1 Ventolin Submarket Forecast 2020-2030
5.1.2.6.2 ProAir Submarket Forecast 2020-2030
5.1.2.6.3 Proventil Submarket Forecast 2020-2030
5.1.2.6.4 Xopenex Submarket Forecast 2020-2030
5.1.2.6.5 Others Submarket Forecast 2020-2030
5.1.2.7 LABA Submarket Forecast 2020-2030
5.1.2.7.1 Foradil Submarket Forecast 2020-2030
5.1.2.7.2 Arcapta/Onbrez Submarket Forecast 2020-2030
5.1.2.7.3 Brovana Submarket Forecast 2020-2030
5.1.2.7.4 Serevent Submarket Forecast 2020-2030
5.1.2.7.5 Others Submarket Forecast 2020-2030
5.1.3 Combination Drugs Submarket Forecast 2020-2030
5.1.3.1 V Shaped Recovery: Global COPD and Asthma Therapies Market for Combination Drugs Segment forecast, 2020 to 2030
5.1.3.2 U Shaped Recovery: Global COPD and Asthma Therapies Market for Combination Drugs Segment forecast, 2020 to 2030
5.1.3.3 W Shaped Recovery: Global COPD and Asthma Therapies Market for Combination Drugs Segment forecast, 2020 to 2030
5.1.3.4 L Shaped Recovery: Global COPD and Asthma Therapies Market for Combination Drugs Segment forecast, 2020 to 2030
5.1.3.5 Advair Submarket Forecast 2020-2030
5.1.3.6 Symbicort Submarket Forecast 2020-2030
5.1.3.7 Combivent Submarket Forecast 2020-2030
5.1.3.8 Dulera Submarket Forecast 2020-2030
5.1.3.9 Relvar/Breo Submarket Forecast 2020-2030
5.1.3.10 Others Submarket Forecast 2020-2030
6 Global COPD and Asthma Therapies Market by Route of administration
6.1 Oral Submarket Forecast 2020-2030
6.1.1 V Shaped Recovery: Global COPD and Asthma Therapies Market for Oral Segment forecast, 2020 to 2030
6.1.2 U Shaped Recovery: Global COPD and Asthma Therapies Market for Oral Segment forecast, 2020 to 2030
6.1.3 W Shaped Recovery: Global COPD and Asthma Therapies Market for Oral Segment forecast, 2020 to 2030
6.1.4 L Shaped Recovery: Global COPD and Asthma Therapies Market for Oral Segment forecast, 2020 to 2030
6.2 Inhaled Submarket Forecast 2020-2030
6.2.1 V Shaped Recovery: Global COPD and Asthma Therapies Market for Inhaled Segment forecast, 2020 to 2030
6.2.2 U Shaped Recovery: Global COPD and Asthma Therapies Market for Inhaled Segment forecast, 2020 to 2030
6.2.3 W Shaped Recovery: Global COPD and Asthma Therapies Market for Inhaled Segment forecast, 2020 to 2030
6.2.4 L Shaped Recovery: Global COPD and Asthma Therapies Market for Inhaled Segment forecast, 2020 to 2030
6.3 Others Submarket Forecast 2020-2030
6.3.1 V Shaped Recovery: Global COPD and Asthma Therapies Market for Others Segment forecast, 2020 to 2030
6.3.2 U Shaped Recovery: Global COPD and Asthma Therapies Market for Others Segment forecast, 2020 to 2030
6.3.3 W Shaped Recovery: Global COPD and Asthma Therapies Market for Others Segment forecast, 2020 to 2030
6.3.4 L Shaped Recovery: Global COPD and Asthma Therapies Market for Others Segment forecast, 2020 to 2030
7 Global COPD and Asthma Therapies Market by Point of Sale
7.1 Retail pharmacies Submarket Forecast 2020-2030
7.1.1 V Shaped Recovery: Global COPD and Asthma Therapies Market for Retail Pharmacies Segment forecast, 2020 to 2030
7.1.2 U Shaped Recovery: Global COPD and Asthma Therapies Market for Retail pharmacies Segment forecast, 2020 to 2030
7.1.3 W Shaped Recovery: Global COPD and Asthma Therapies Market for Retail pharmacies Segment forecast, 2020 to 2030
7.1.4 L Shaped Recovery: Global COPD and Asthma Therapies Market for Retail pharmacies Segment forecast, 2020 to 2030
7.2 Hospital pharmacies Submarket Forecast 2020-2030
7.2.1 V Shaped Recovery: Global COPD and Asthma Therapies Market for Hospital pharmacies Segment forecast, 2020 to 2030
7.2.2 U Shaped Recovery: Global COPD and Asthma Therapies Market for Hospital pharmacies Segment forecast, 2020 to 2030
7.2.3 W Shaped Recovery: Global COPD and Asthma Therapies Market for Hospital pharmacies Segment forecast, 2020 to 2030
7.2.4 L Shaped Recovery: Global COPD and Asthma Therapies Market for Hospital pharmacies Segment forecast, 2020 to 2030
7.3 Others Submarket Forecast 2020-2030
7.3.1 V Shaped Recovery: Global COPD and Asthma Therapies Market for Others Segment forecast, 2020 to 2030
7.3.2 U Shaped Recovery: Global COPD and Asthma Therapies Market for Others Segment forecast, 2020 to 2030
7.3.3 W Shaped Recovery: Global COPD and Asthma Therapies Market for Others Segment forecast, 2020 to 2030
7.3.4 L Shaped Recovery: Global COPD and Asthma Therapies Market for Others Segment forecast, 2020 to 2030
8 Regional and Leading National COPD and Asthma Therapies Forecasts 2020-2030
8.1 Global COPD and Asthma Therapies by National Market Share Forecast 2020-2030
9 North America COPD and Asthma Therapies Forecast 2020-2030
9.1.1 North America COPD and Asthma Therapies Market: Revenue Forecast, V Shaped Recovery
9.1.2 North America COPD and Asthma Therapies Market: Revenue Forecast, U Shaped Recovery
9.1.3 North America COPD and Asthma Therapies Market: Revenue Forecast, W Shaped Recovery
9.1.4 North America COPD and Asthma Therapies Market: Revenue Forecast, L Shaped Recovery
9.1.5 U.S. COPD and Asthma Therapies Forecast 2020-2030
9.1.5.1 U.S. COPD and Asthma Therapies Market: Revenue Forecast, V Shaped Recovery
9.1.5.2 U.S. COPD and Asthma Therapies Market: Revenue Forecast, U Shaped Recovery
9.1.5.3 U.S. COPD and Asthma Therapies Market: Revenue Forecast, W Shaped Recovery
9.1.5.4 U.S. COPD and Asthma Therapies Market: Revenue Forecast, L Shaped Recovery
9.1.6 Canada COPD and Asthma Therapies Forecast 2020-2030
9.1.6.1 Canada COPD and Asthma Therapies Market: Revenue Forecast, V Shaped Recovery
9.1.6.2 Canada COPD and Asthma Therapies Market: Revenue Forecast, U Shaped Recovery
9.1.6.3 Canada COPD and Asthma Therapies Market: Revenue Forecast, W Shaped Recovery
9.1.6.4 Canada COPD and Asthma Therapies Market: Revenue Forecast, L Shaped Recovery
10 Europe COPD and Asthma Therapies Forecast 2020-2030
10.1.1 Europe COPD and Asthma Therapies Market: Revenue Forecast, V Shaped Recovery
10.1.2 Europe COPD and Asthma Therapies Market: Revenue Forecast, U Shaped Recovery
10.1.3 Europe COPD and Asthma Therapies Market: Revenue Forecast, W Shaped Recovery
10.1.4 Europe COPD and Asthma Therapies Market: Revenue Forecast, L Shaped Recovery
10.1.5 Germany COPD and Asthma Therapies Forecast 2020-2030
10.1.5.1 Germany COPD and Asthma Therapies Market: Revenue Forecast, V Shaped Recovery
10.1.5.2 Germany COPD and Asthma Therapies Market: Revenue Forecast, U Shaped Recovery
10.1.5.3 Germany COPD and Asthma Therapies Market: Revenue Forecast, W Shaped Recovery
10.1.5.4 Germany COPD and Asthma Therapies Market: Revenue Forecast, L Shaped Recovery
10.1.6 France COPD and Asthma Therapies Forecast 2020-2030
10.1.6.1 France COPD and Asthma Therapies Market: Revenue Forecast, V Shaped Recovery
10.1.6.2 France COPD and Asthma Therapies Market: Revenue Forecast, U Shaped Recovery
10.1.6.3 France COPD and Asthma Therapies Market: Revenue Forecast, W Shaped Recovery
10.1.6.4 France COPD and Asthma Therapies Market: Revenue Forecast, L Shaped Recovery
10.1.7 UK COPD and Asthma Therapies Forecast 2020-2030
10.1.7.1 UK COPD and Asthma Therapies Market: Revenue Forecast, V Shaped Recovery
10.1.7.2 UK COPD and Asthma Therapies Market: Revenue Forecast, U Shaped Recovery
10.1.7.3 UK COPD and Asthma Therapies Market: Revenue Forecast, W Shaped Recovery
10.1.7.4 UK COPD and Asthma Therapies Market: Revenue Forecast, L Shaped Recovery
10.1.8 Spain COPD and Asthma Therapies Forecast 2020-2030
10.1.8.1 Spain COPD and Asthma Therapies Market: Revenue Forecast, V Shaped Recovery
10.1.8.2 Spain COPD and Asthma Therapies Market: Revenue Forecast, U Shaped Recovery
10.1.8.3 Spain COPD and Asthma Therapies Market: Revenue Forecast, W Shaped Recovery
10.1.8.4 Spain COPD and Asthma Therapies Market: Revenue Forecast, L Shaped Recovery
10.1.9 Italy COPD and Asthma Therapies Forecast 2020-2030
10.1.9.1 Italy COPD and Asthma Therapies Market: Revenue Forecast, V Shaped Recovery
10.1.9.2 Italy COPD and Asthma Therapies Market: Revenue Forecast, U Shaped Recovery
10.1.9.3 Italy COPD and Asthma Therapies Market: Revenue Forecast, W Shaped Recovery
10.1.9.4 Italy COPD and Asthma Therapies Market: Revenue Forecast, L Shaped Recovery
10.1.10 Rest of Europe COPD and Asthma Therapies Forecast 2020-2030
10.1.10.1 Rest of Europe COPD and Asthma Therapies Market: Revenue Forecast, V Shaped Recovery
10.1.10.2 Rest of Europe COPD and Asthma Therapies Market: Revenue Forecast, U Shaped Recovery
10.1.10.3 Rest of Europe COPD and Asthma Therapies Market: Revenue Forecast, W Shaped Recovery
10.1.10.4 Rest of Europe COPD and Asthma Therapies Market: Revenue Forecast, L Shaped Recovery
11 APAC COPD and Asthma Therapies Forecast 2020-2030
11.1.1 APAC COPD and Asthma Therapies Market: Revenue Forecast, V Shaped Recovery
11.1.2 APAC COPD and Asthma Therapies Market: Revenue Forecast, U Shaped Recovery
11.1.3 APAC COPD and Asthma Therapies Market: Revenue Forecast, W Shaped Recovery
11.1.4 APAC COPD and Asthma Therapies Market: Revenue Forecast, L Shaped Recovery
11.1.5 China COPD and Asthma Therapies Forecast 2020-2030
11.1.5.1 China COPD and Asthma Therapies Market: Revenue Forecast, V Shaped Recovery
11.1.5.2 China COPD and Asthma Therapies Market: Revenue Forecast, U Shaped Recovery
11.1.5.3 China COPD and Asthma Therapies Market: Revenue Forecast, W Shaped Recovery
11.1.5.4 China COPD and Asthma Therapies Market: Revenue Forecast, L Shaped Recovery
11.1.6 Japan COPD and Asthma Therapies Forecast 2020-2030
11.1.6.1 Japan COPD and Asthma Therapies Market: Revenue Forecast, V Shaped Recovery
11.1.6.2 Japan COPD and Asthma Therapies Market: Revenue Forecast, U Shaped Recovery
11.1.6.3 Japan COPD and Asthma Therapies Market: Revenue Forecast, W Shaped Recovery
11.1.6.4 Japan COPD and Asthma Therapies Market: Revenue Forecast, L Shaped Recovery
11.1.7 India COPD and Asthma Therapies Forecast 2020-2030
11.1.7.1 India COPD and Asthma Therapies Market: Revenue Forecast, V Shaped Recovery
11.1.7.2 India COPD and Asthma Therapies Market: Revenue Forecast, U Shaped Recovery
11.1.7.3 India COPD and Asthma Therapies Market: Revenue Forecast, W Shaped Recovery
11.1.7.4 India COPD and Asthma Therapies Market: Revenue Forecast, L Shaped Recovery
11.1.8 Rest of APAC COPD and Asthma Therapies Forecast 2020-2030
11.1.8.1 Rest of APAC COPD and Asthma Therapies Market: Revenue Forecast, V Shaped Recovery
11.1.8.2 Rest of APAC COPD and Asthma Therapies Market: Revenue Forecast, U Shaped Recovery
11.1.8.3 Rest of APAC COPD and Asthma Therapies Market: Revenue Forecast, W Shaped Recovery
11.1.8.4 Rest of APAC COPD and Asthma Therapies Market: Revenue Forecast, L Shaped Recovery
12 Rest of the World COPD and Asthma Therapies Forecast 2020-2030
12.1.1 Rest of the World COPD and Asthma Therapies Market: Revenue Forecast, V Shaped Recovery
12.1.2 Rest of the World COPD and Asthma Therapies Market: Revenue Forecast, U Shaped Recovery
12.1.3 Rest of the World COPD and Asthma Therapies Market: Revenue Forecast, W Shaped Recovery
12.1.4 Rest of the World COPD and Asthma Therapies Market: Revenue Forecast, L Shaped Recovery
13 Leading Companies in the COPD and Asthma Therapies
13.1 How Will Leading Companies’ Market Shares Change to 2030?
13.2 AstraZeneca
13.2.1 AstraZeneca: Company Overview
13.2.2 AstraZeneca: Financials, 2016-2019
13.2.3 Products / Services
13.2.4 Latest developments related to Key Marketed Products
13.2.4.1 Symbicort: Recent Developments
13.2.4.2 Bevespi Aerosphere: Recent Developments
13.2.4.3 Tudorza/ Eklira Genuair: Recent Developments
13.2.4.4 Duaklir: Recent Developments
13.2.4.5 Fasenra: Recent Developments
13.2.4.6 Other Recent Developments
13.2.5 AstraZeneca, Asthma & COPD Products- R&D Pipeline & Future Outlook
13.3 GlaxoSmithKline
13.3.1 GlaxoSmithKline: Company Overview
13.3.2 GlaxoSmithKline: Financials, 2016-2019
13.3.3 Products / Services
13.3.4 Latest developments related to Key Marketed Products
13.3.4.1 Once-daily Trelegy Ellipta: Recent Developments
13.3.4.2 Trelegy Ellipta: Recent Developments
13.3.4.3 Anoro Ellipta: Recent Developments
13.3.4.4 Nucala: Recent Developments
13.3.4.5 Seretide/Advair: Recent Developments
13.3.4.6 Trelegy Ellipta: Recent Developments
13.3.4.7 Breo Ellipta, Advair Diskus and Advair HFA: Recent Developments
13.4 Boehringer Ingelheim
13.4.1 Boehringer Ingelheim: Company Overview
13.4.2 Boehringer Ingelheim: Financials, 2016-2019
13.4.3 Products / Services
13.4.4 Latest developments related to Key Marketed Products
13.4.4.1 Aservo® EquiHaler: Recent Developments
13.4.4.2 Spiolto Respimat: Recent Developments
13.4.4.3 Spiriva Respimat: Recent Developments
13.4.4.4 Ofev: Recent Developments
13.4.4.5 Boehringer Ingelheim, Asthma & COPD Products- R&D Pipeline & Future Outlook
13.5 Teva
13.5.1 Teva: Company Overview
13.5.2 Teva: Financials, 2016-2019
13.5.3 Products / Services
13.5.4 Latest developments related to Key Marketed Products
13.5.4.1 QVAR: Recent Developments
13.5.4.2 QVAR: Recent Developments
13.5.4.3 DuoResp Spiromax: Recent Developments
13.5.4.4 Aerivio Spiromax: Recent Developments
13.6 Merck
13.6.1 Merck: Company Overview
13.6.2 Merck: Financials, 2016-2019
13.6.3 Products / Services
13.6.4 Latest developments related to Key Marketed Products
13.6.4.1 Dulera: Recent Development
13.7 F.Hoffmann-La Roche AG
13.7.1 F. Hoffmann-La Roche AG: Company Overview
13.7.2 F. Hoffmann-La Roche AG: Financials, 2016-2019
13.7.3 Products / Services
13.7.4 Latest developments related to Key Marketed Products
13.7.4.1 Xolair: Recent Developments
13.8 Novartis
13.8.1 Novartis: Company Overview
13.8.2 Novartis: Financials, 2016-2019
13.8.3 Products / Services
13.8.4 Latest developments related to Key Marketed Products
13.8.4.1 Ultibro Breezhaler: Recent Developments
13.8.4.2 Ultibro Breezhaler: Recent Developments
13.8.4.3 Xolair: Recent Developments
13.9 Mundipharma
13.9.1 Mundipharma: Company Overview
13.9.2 Products / Services
13.9.3 Latest developments related to Key Marketed Products
13.9.3.1 Flutiform (fluticasone propionate and formoterol): Recent Developments
13.9.3.2 Company Related Developments
13.10 Cipla
13.10.1 Cipla: Company Overview
13.10.2 Cipla: Financials, 2016-2019
13.10.3 Products / Services
13.10.4 Mergers & Acquisitions (M&A) Activity
13.10.5 Latest developments related to Key Marketed Products
13.10.5.1 Budesonide Inhalation Suspension: Pipeline Developments
13.10.5.2 SynchroBreathe: Pipeline Developments
13.10.6 Cipla Launch Plans for Respiratory Products
13.10.7 Sunovion Pharmaceuticals: Company Overview
13.10.8 Products / Services
13.10.9 Latest developments related to Key Marketed Products
13.10.9.1 SUN-101: Recent Developments
13.10.9.2 Sunovion Pharmaceuticals, Asthma & COPD Products- R&D Pipeline & Future Outlook
13.10.9.3 Sunovion -Asthma & COPD Market Forecast, 2019-2030
13.11 Pulmatrix
13.11.1 Pulmatrix: Company Overview
13.11.2 Pulmatrix: Financials, 2016-2019
13.11.3 Products / Services
13.11.4 Latest developments related to Key Pipeline Products
13.11.4.1 PUR0200-US: Recent development
13.11.4.2 PUR0200-US: Recent development
13.11.4.3 PUR1900: Recent development
13.12 TFF PHARMACEUTICALS, INC
13.12.1 TFF PHARMACEUTICALS, INC: Company Overview
13.12.2 Products / Services
13.12.3 Latest developments related to the pipeline products
13.12.3.1 TFF TRIPLE COMBINATION: Recent developments
13.13 Respiratorius AB
13.13.1 Respiratorius AB: Company Overview
13.13.2 Products / Services
13.13.3 Latest developments related to the pipeline products
13.13.3.1 Product: Recent developments
14 Conclusions and Recommendations
14.1 Conclusions
14.2 Recommendations
14.3 Associated Visiongain Reports
15 Glossary
List of Figures
Figure 1. GLOBAL COPD AND ASTHMA THERAPIES REVENUE FORECAST 2020-2030 (US $ MILLION, AGR%)
Figure 2. GLOBAL COPD AND ASTHMA THERAPIES MARKET SHARE, 2019
Figure 3. SUMMARY OF GINA GUIDANCE FOR ASTHMA TREATMENT, 2019
Figure 4. SUMMARY OF GOLD GUIDANCE FOR COPD TREATMENT, 2019
Figure 5. GLOBAL COPD AND ASTHMA THERAPIES REVENUE FORECAST 2020-2030 (US $ MILLION, AGR%)
Figure 6. MARKET DRIVERS
Figure 7. PORTER’S FIVE FORCES
Figure 8. COPD AND ASTHMA THERAPIES MARKET BY TREATMENT
Figure 9. GLOBAL COPD AND ASTHMA THERAPIES REVENUE FORECAST 2020-2030 TREATMENT (%)
Figure 10. GLOBAL COPD AND ASTHMA THERAPIES REVENUE FORECAST 2020-2030 TREATMENT (%)
Figure 11. GLOBAL MEDICATION REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %)
Figure 12. GLOBAL ANTI-INFLAMMATORY DRUGS REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %)
Figure 13. V SHAPED RECOVERY: GLOBAL COPD AND ASTHMA THERAPIES MARKET FOR ANTI-INFLAMMATORY SEGMENT FORECAST, 2020 TO 2030
Figure 14. U SHAPED RECOVERY: GLOBAL COPD AND ASTHMA THERAPIES MARKET FOR ANTI-INFLAMMATORY SEGMENT FORECAST, 2020 TO 2030
Figure 15. W SHAPED RECOVERY: GLOBAL COPD AND ASTHMA THERAPIES MARKET FOR ANTI-INFLAMMATORY SEGMENT FORECAST, 2020 TO 2030
Figure 16. L SHAPED RECOVERY: GLOBAL COPD AND ASTHMA THERAPIES MARKET FOR ANTI-INFLAMMATORY SEGMENT FORECAST, 2020 TO 2030
Figure 17. GLOBAL CORTICOSTEROIDS REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %)
Figure 18. GLOBAL PULMICORT REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %)
Figure 19. GLOBAL FLIXOTIDE REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %)
Figure 20. GLOBAL QVAR REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %)
Figure 21. GLOBAL ASMANEX REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %)
Figure 22. GLOBAL OTHERS REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %)
Figure 23. GLOBAL ANTI-LEUKOTRIENES REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %)
Figure 24. GLOBAL SINGULAIR REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %)
Figure 25. GLOBAL OTHERS REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %)
Figure 26. GLOBAL MONOCLONAL ANTIBODIES REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %)
Figure 27. GLOBAL XOLAIR REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %)
Figure 28. GLOBAL CINQAIR REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %)
Figure 29. GLOBAL NUCALA REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %)
Figure 30. GLOBAL BENRALIZUMAB REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %)
Figure 31. GLOBAL LEBRIKIZUMAB REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %)
Figure 32. GLOBAL DUPILUMAB REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %)
Figure 33. GLOBAL BRONCHODILATOR MONOTHERAPY REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %)
Figure 34. V SHAPED RECOVERY: GLOBAL COPD AND ASTHMA THERAPIES MARKET FOR BRONCHODILATOR MONOTHERAPY SEGMENT FORECAST, 2020 TO 2030
Figure 35. U SHAPED RECOVERY: GLOBAL COPD AND ASTHMA THERAPIES MARKET FOR BRONCHODILATOR MONOTHERAPY SEGMENT FORECAST, 2020 TO 2030
Figure 36. W SHAPED RECOVERY: GLOBAL COPD AND ASTHMA THERAPIES MARKET FOR BRONCHODILATOR MONOTHERAPY SEGMENT FORECAST, 2020 TO 2030
Figure 37. L SHAPED RECOVERY: GLOBAL COPD AND ASTHMA THERAPIES MARKET FOR BRONCHODILATOR MONOTHERAPY SEGMENT FORECAST, 2020 TO 2030
Figure 38. GLOBAL ANTICHOLINERGICS REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %)
Figure 39. GLOBAL SPIRIVA REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %)
Figure 40. GLOBAL ATROVENT REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %)
Figure 41. GLOBAL EKLIRA REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %)
Figure 42. GLOBAL OTHERS REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %)
Figure 43. GLOBAL SABA REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %)
Figure 44. GLOBAL VENTOLIN REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %)
Figure 45. GLOBAL PROAIR REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %)
Figure 46. GLOBAL PROVENTIL REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %)
Figure 47. GLOBAL XOPENEX REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %)
Figure 48. GLOBAL OTHERS REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %)
Figure 49. GLOBAL LABA REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %)
Figure 50. GLOBAL FORADIL REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %)
Figure 51. GLOBAL ARCAPTA/ONBREZ REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %)
Figure 52. GLOBAL BROVANA REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %)
Figure 53. GLOBAL SEREVENT REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %)
Figure 54. GLOBAL OTHERS REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %)
Figure 55. GLOBAL COMBINATION DRUGS REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %)
Figure 56. V SHAPED RECOVERY: GLOBAL COPD AND ASTHMA THERAPIES MARKET FOR COMBINATION DRUGS SEGMENT FORECAST, 2020 TO 2030
Figure 57. U SHAPED RECOVERY: GLOBAL COPD AND ASTHMA THERAPIES MARKET FOR COMBINATION DRUGS SEGMENT FORECAST, 2020 TO 2030
Figure 58. W SHAPED RECOVERY: GLOBAL COPD AND ASTHMA THERAPIES MARKET FOR COMBINATION DRUGS SEGMENT FORECAST, 2020 TO 2030
Figure 59. L SHAPED RECOVERY: GLOBAL COPD AND ASTHMA THERAPIES MARKET FOR COMBINATION DRUGS SEGMENT FORECAST, 2020 TO 2030
Figure 60. GLOBAL ADVAIR REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %)
Figure 61. GLOBAL SYMBICORT REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %)
Figure 62. GLOBAL COMBIVENT REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %)
Figure 63. GLOBAL DULERA REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %)



★調査レポート[喘息・COPD療法の世界市場2020-2030] (コード:VGA20DE020)販売に関する免責事項を必ずご確認ください。
★調査レポート[喘息・COPD療法の世界市場2020-2030]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆